Marfan Syndrome

  1. Overview and Epidemiology
  2. Genetics: FBN1 and the TGF-β Paradox
  3. Cardiovascular Manifestations
  4. Ocular Manifestations
  5. Skeletal Manifestations
  6. Revised Ghent Nosology: Diagnostic Criteria
  7. Differential Diagnosis
  8. Medical Management
  9. Surgical Management
  10. Pregnancy and Special Populations
  11. Key Research Papers
  12. Connections
  13. Featured Videos

Overview and Epidemiology

Marfan syndrome is an autosomal dominant hereditary connective tissue disorder caused by mutations in FBN1 (fibrillin-1, chromosome 15q21.1). It occurs in approximately 1 in 5,000 persons, affects all ethnic groups equally, and occurs equally in males and females. The condition is named after French pediatrician Antoine Marfan, who in 1896 described the first case — a 5-year-old girl with unusually long, slender limbs and fingers.

Inheritance is autosomal dominant: 75% of cases are inherited from an affected parent, while 25% arise as de novo mutations. Expressivity is highly variable — even within the same family, affected individuals can range from severely affected to nearly asymptomatic. The hallmark physical appearance — tall stature, long limbs, arachnodactyly (spider-like fingers) — has prompted retrospective speculation that Abraham Lincoln, Niccolò Paganini, and Franz Liszt may have had Marfan syndrome, though these claims remain unconfirmed.

Without treatment, the median survival was historically approximately 40 years, with death most often caused by type A aortic dissection — a surgical emergency involving the ascending aorta. Modern medical and surgical management has extended life expectancy to near-normal for patients identified and treated appropriately. The most dangerous complication remains type A aortic dissection (Stanford classification: involves ascending aorta), which can strike young adults during exertion and carries high mortality without emergency surgery.

Back to Table of Contents

Genetics: FBN1 and the TGF-β Paradox

FBN1 encodes fibrillin-1, a glycoprotein that is the principal structural component of microfibrils in the extracellular matrix. These microfibrils form the scaffold for elastin fibers and are particularly abundant in the aorta, periosteum, ciliary zonules of the eye, lung, and skin — which explains why these tissues are disproportionately affected in Marfan syndrome.

Two distinct mechanistic models explain Marfan pathology:

More than 3,000 FBN1 mutations have been identified. Genotype-phenotype correlations are imperfect but some patterns are recognized: mutations in exons 24–32 are associated with neonatal Marfan syndrome — the most severe form, with early-onset cardiovascular failure. Missense mutations in EGF-like domains are the most common class overall.

Conditions within the Marfan spectrum include:

Back to Table of Contents

Cardiovascular Manifestations

Cardiovascular disease is the leading cause of morbidity and mortality in Marfan syndrome. The aorta is the primary target; the mitral valve is the second most affected cardiac structure.

Aortic root dilation is the central and most dangerous cardiovascular feature. The aorta dilates progressively at the sinuses of Valsalva (the level of the aortic valve annulus and leaflet attachment points). Dilation is quantified as a Z-score — the number of standard deviations above the mean corrected for age and body surface area. A Z-score ≥2 meets the Revised Ghent diagnostic criterion. In adults on medical therapy, the typical progression rate is 0.5–1 mm per year.

Type A aortic dissection is the most feared complication. It presents classically as sudden severe "tearing" chest or back pain, unequal pulses, and new aortic regurgitation. Most dissections in Marfan syndrome occur when the aortic root diameter reaches 45–55 mm. This is a surgical emergency requiring immediate repair (Bentall procedure or valve-sparing root replacement). Risk factors for dissection include:

Mitral valve prolapse (MVP) affects 50–80% of Marfan patients, caused by myxomatous degeneration and redundancy of the mitral leaflets. Clinically, this produces a mid-systolic click and late systolic murmur. Significant mitral regurgitation requiring surgery occurs in approximately 25% of patients with MVP.

Aortic regurgitation develops secondary to progressive aortic root dilation, as the dilating root pulls the aortic valve leaflets apart. This imposes a volume load on the left ventricle and — if severe — accelerates the need for surgical intervention.

Additional cardiovascular features include:

Surveillance: Annual echocardiogram is recommended for all patients. When the aortic root exceeds 45 mm, 6-monthly echocardiography is preferred. CT or MRI aortography at baseline images the entire aorta to detect arch or descending involvement not visible on echo.

Back to Table of Contents

Ocular Manifestations

Ectopia lentis (dislocation of the crystalline lens) is the characteristic ocular finding of Marfan syndrome, present in approximately 60% of patients. It is caused by fibrillin-1 deficiency in the ciliary zonules — the fine fibers that suspend the lens. When these zonules weaken, the lens displaces from its normal position.

The direction of dislocation is diagnostically important: in Marfan syndrome, the lens typically dislocates superiorly and temporally. This contrasts with homocystinuria, where the lens dislocates inferiorly and nasally — a critical point for differential diagnosis. The Marfan lens rarely dislocates fully into the anterior chamber.

Consequences of ectopia lentis include:

Myopia is nearly universal in Marfan syndrome, often high (>6 diopters), caused by both axial elongation of the globe and ectopia lentis. The elongated globe significantly increases the risk of retinal detachment — both spontaneous and post-surgical. Prophylactic laser retinopexy (treating areas of lattice degeneration) and activity restriction reduce this risk.

Glaucoma — both open-angle and angle-closure — occurs at elevated frequency. Angle closure can be precipitated acutely by anterior lens dislocation. Regular intraocular pressure monitoring is warranted.

An important point for ophthalmologic care: LASIK refractive surgery is contraindicated in Marfan syndrome. The corneas are typically flatter than normal and the ongoing myopia progression — combined with thin corneas — make LASIK unsafe. Annual ophthalmology evaluations are recommended for all patients.

Back to Table of Contents

Skeletal Manifestations

Connective tissue involvement in periosteum and growth plates drives excessive longitudinal bone growth, producing the distinctive Marfan skeletal habitus. These features form the basis of the systemic score used in the Revised Ghent Nosology.

Tall stature with disproportionately long limbs is characteristic. The upper segment to lower segment (US/LS) ratio is reduced (long lower limbs relative to torso); a ratio <0.85 in adults (normal ~1.0) is typical. The arm span-to-height ratio clearly exceeds 1.05 in most affected individuals, as arm span exceeds height.

Arachnodactyly (spider-like fingers) is assessed by two bedside clinical signs, both part of the Ghent systemic score:

Scoliosis is present in approximately 60% of patients. It is progressive during growth and can impair pulmonary function when severe. Curves exceeding 40–45° may require surgical correction.

Pectus deformities are common: pectus excavatum (inward depression of the sternum, more common) or pectus carinatum ("pigeon chest," protrusion). Severe pectus excavatum can impair cardiac filling and lung expansion, and carries 2 systemic-score points (carinatum) or 1 point (excavatum).

Dural ectasia — enlargement of the sacral dural sac — is present in approximately 90% of adults with Marfan syndrome. It reflects fibrillin-1 deficiency in spinal dural connective tissue and can cause lumbosacral pain, proximal leg weakness, and numbness. Diagnosis requires MRI (not CT). It carries 2 points on the Ghent systemic score.

Additional skeletal features include:

Back to Table of Contents

Revised Ghent Nosology: Diagnostic Criteria

The Revised Ghent Nosology (2010, Loeys et al., PMID 20591885) replaced the 1996 original Ghent criteria with a simplified framework that emphasizes the two most specific features: aortic root dilation/dissection and ectopia lentis, supplemented by FBN1 molecular testing and a systemic feature score.

In the absence of family history, Marfan syndrome is diagnosed in any of four scenarios:

  1. Aortic root dilation (Z-score ≥2 at sinuses of Valsalva, or aortic dissection) AND ectopia lentis — regardless of other findings or FBN1 status
  2. Aortic root dilation (Z-score ≥2 or dissection) AND a pathogenic FBN1 mutation — regardless of systemic score
  3. Aortic root dilation (Z-score ≥2 or dissection) AND systemic score ≥7 — if no FBN1 mutation found or testing not done
  4. Ectopia lentis AND a pathogenic FBN1 mutation known to be associated with aortic disease — even without current aortic dilation

With a confirmed family history of Marfan syndrome (first-degree relative meeting independent criteria): ectopia lentis alone, systemic score ≥7 alone, or aortic root dilation (Z-score ≥2) alone is sufficient for diagnosis in that relative.

The systemic score (maximum 20 points) assigns points as follows:

A systemic score ≥7 supports the diagnosis in the appropriate cardiovascular context. The Z-score cutoff of ≥2 means the aortic root is 2 or more standard deviations above the mean for age and body surface area. Most adults with Marfan syndrome have Z-scores of 2–5+; a Z-score >4 carries a very high positive predictive value.

Back to Table of Contents

Differential Diagnosis

Several heritable connective tissue disorders overlap substantially with Marfan syndrome, making careful phenotyping and molecular testing essential.

Loeys-Dietz Syndrome (LDS) — caused by mutations in TGFBR1 or TGFBR2 (and other TGF-β pathway genes). Overlapping features include tall stature, aortic root dilation, and scoliosis. Distinguishing features of LDS: hypertelorism (widely spaced eyes), bifid uvula or cleft palate, arterial tortuosity throughout the body (extending beyond the aortic root), and aneurysms at multiple arterial sites. Critically, LDS carries a more aggressive vascular phenotype — surgery is recommended at smaller aortic diameters (42–45 mm) compared to Marfan (50 mm). LDS lacks ectopia lentis.

Ehlers-Danlos Syndrome, vascular type (vEDS) — caused by COL3A1 mutations (type III collagen). The defining danger is spontaneous arterial rupture without pre-existing aneurysm. Unlike Marfan syndrome, vEDS does not cause ectopia lentis or major skeletal overgrowth. Distinctive features: translucent skin, characteristic facial features (thin lips, prominent eyes, lobeless ears, small chin), easy bruising.

Homocystinuria — autosomal recessive disorder of the CBS gene (cystathionine beta-synthase deficiency). Phenotypically overlaps with Marfan (tall stature, arachnodactyly, ectopia lentis, scoliosis). The key differentiators: lens dislocation is inferior and nasal (vs. superior-temporal in Marfan); intellectual disability is common; thromboembolic events (venous and arterial) are a major risk; and urine amino acid analysis shows markedly elevated homocysteine. Treatable with pyridoxine (B6), B12, folate, or betaine.

MASS syndrome — Marfan-like features (Myopia, MVP, borderline Aortic Z-score, Striae, Skeletal features) that do not meet full Revised Ghent criteria. Z-score typically 1.5–2.0, no ectopia lentis. Managed expectantly with periodic surveillance.

Bicuspid aortic valve (BAV) with aortic dilation — isolated aortic root or ascending aortic dilation associated with a bicuspid aortic valve. No ectopia lentis, no systemic connective tissue features, no FBN1 mutation. Distinguishing by echocardiography is straightforward. Surgical thresholds differ from Marfan.

Shprintzen-Goldberg syndrome — caused by FBN1 or SKI mutations. Shares Marfan-like skeletal features but adds craniosynostosis and severe intellectual disability — features absent in classic Marfan.

Back to Table of Contents

Medical Management

Medical management targets the two key drivers of morbidity: progressive aortic root dilation and hemodynamic stress on the aortic wall. The overarching goals are to slow aortic dilation, prevent dissection, and control cardiovascular complications.

Beta-blockers (atenolol or propranolol) have been first-line therapy for decades. They reduce heart rate, blood pressure, and — most importantly — dP/dt (the rate of pressure rise in the aorta during systole), which is the primary mechanical stress driver of progressive dilation. Beta-blockers should be started at diagnosis in all patients with aortic root dilation and are continued lifelong. Target resting heart rate is typically 60–70 bpm.

Losartan (angiotensin receptor blocker, ARB) blocks the AT1 receptor and downstream TGF-β signaling, directly addressing the mechanistic paradox described above. Major clinical trials:

Most centers now use losartan or another ARB as an alternative or adjunct to beta-blockade. Some prescribe both agents in combination. The target blood pressure is <110 mmHg systolic in adults.

Activity restrictions are essential and sometimes difficult for patients to accept:

Medications to avoid: decongestants (pseudoephedrine), illicit stimulants (cocaine, amphetamines), and any agent that causes acute blood pressure surges. NSAIDs should be used cautiously if anticoagulation is being considered post-surgery.

Annual surveillance includes echocardiogram, ophthalmology evaluation, and orthopedic assessment. MRI of the spine is appropriate when dural ectasia symptoms are present. Genetic counseling is recommended for all patients and their families.

Back to Table of Contents

Surgical Management

Prophylactic aortic root replacement before dissection occurs is the intervention that most dramatically improves survival in Marfan syndrome. Timing follows evidence-based diameter thresholds.

Elective aortic root replacement thresholds:

Valve-sparing root replacement (VSRR) — the David procedure or Yacoub remodeling — is the preferred approach in young patients with a structurally competent aortic valve. The native valve is preserved while the aortic root and sinuses are replaced with a Dacron graft. This avoids lifelong anticoagulation. Long-term freedom from valve re-operation exceeds 90% at 10 years in experienced centers (David et al., 2014, JACC, PMID 24384138).

Bentall procedure (composite graft replacement) replaces the aortic root and valve with a mechanical prosthesis. Preferred when the aortic valve is structurally abnormal, severely regurgitant, or when technical factors preclude VSRR. Requires lifelong anticoagulation with warfarin (target INR 2.5–3.5). Long-term outcomes are excellent — Gott et al. (1999, NEJM, PMID 10228192) reported 675 Marfan patients undergoing root replacement, with 5-year survival of 75%.

Mitral valve surgery: Repair is strongly preferred over replacement. Timing follows standard heart failure/valvular guidelines (severe MR with LV dysfunction, symptoms, or LV dilation). Many centers with Marfan expertise achieve excellent long-term repair durability using fibrous annular reconstruction techniques.

Aortic arch and descending aorta: The entire remaining aorta is at lifelong risk after root replacement. If dissection or aneurysm involves the arch or descending thoracic aorta, open surgical or hybrid approaches are used. TEVAR (thoracic endovascular aortic repair) is generally avoided as a primary strategy in classic Marfan syndrome due to the friable aortic wall and risk of retrograde type A dissection — it is used cautiously and selectively at specialized centers.

Post-operative surveillance: Annual CT or MRI of the entire aorta is mandatory after root replacement. The proximal aorta has been replaced, but the downstream aorta continues to enlarge and must be monitored indefinitely.

Scoliosis surgery: Spinal fusion is considered for progressive curves exceeding 45–50°. The connective tissue quality in Marfan syndrome requires experienced surgical teams and careful instrumentation choices.

Back to Table of Contents

Pregnancy and Special Populations

Pregnancy represents the highest-risk period for aortic dissection in women with Marfan syndrome. The third trimester and peripartum period are especially dangerous, driven by increased cardiac output, expanded blood volume, and relaxin-mediated softening of vessel wall connective tissue — all of which amplify mechanical stress on an already-vulnerable aorta.

Pre-pregnancy counseling is mandatory:

Management during pregnancy: Echocardiogram is recommended every trimester (and more frequently if the aortic root is >40 mm). Beta-blockers — labetalol or metoprolol — are safe in pregnancy and should be continued throughout. ARBs are absolutely contraindicated (fetal renal toxicity and oligohydramnios). Blood pressure control remains critical.

Delivery planning: Cesarean delivery is typically recommended when the aortic root is ≥40 mm or when there has been prior dissection. For smaller aortic roots, vaginal delivery with epidural anesthesia and passive (assisted) second-stage pushing is acceptable — the goal is to minimize the Valsalva-induced aortic pressure spikes of active pushing.

Neonatal Marfan syndrome — the most severe form — results from FBN1 mutations in exons 24–32. It presents at birth or in utero with cardiac failure, severe mitral and tricuspid valve insufficiency, ectopia lentis, loose skin folds, and joint contractures. It is often fatal in infancy despite intensive intervention.

Pediatric Marfan: Early detection at birth or in infancy enables beta-blocker prophylaxis and ophthalmologic surveillance to begin during the critical developmental window. Growth hormone therapy is not recommended in pediatric Marfan syndrome because it would also accelerate aortic growth.

Psychological impact: The diagnosis of Marfan syndrome carries significant psychological burden — activity restrictions, awareness of potentially fatal complications, and concerns about passing the condition to children. Patient societies (The Marfan Foundation) provide peer support, education, and advocacy. Psychological counseling should be offered routinely alongside medical management.

Back to Table of Contents

Key Research Papers

  1. Loeys BL et al. (2010) — The revised Ghent nosology for the Marfan syndrome. J Med Genet.
    PMID: 20591885
  2. Judge DP, Dietz HC (2005) — Marfan's syndrome. Lancet.
    PMID: 16368670
  3. Dietz HC et al. (1991) — Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene. Nature.
    PMID: 1852208
  4. Neptune ER et al. (2003) — Dysregulation of TGF-β activation contributes to pathogenesis in Marfan syndrome. Nat Genet.
    PMID: 12598898
  5. Brooke BS et al. (2008) — Angiotensin II blockade and aortic-root dilation in Marfan's syndrome. N Engl J Med.
    PMID: 18256394
  6. Lacro RV et al. (2014) — Atenolol versus losartan in children and young adults with Marfan's syndrome. N Engl J Med.
    PMID: 25405392
  7. Mullen M et al. (2019) — Irbesartan in Marfan syndrome (AIMS): a double-blind, placebo-controlled randomised trial. Lancet.
    PMID: 30773219
  8. Silverman DI et al. (1995) — Life expectancy in the Marfan syndrome. Am J Cardiol.
    PMID: 7677129
  9. David TE et al. (2014) — Outcomes of aortic valve-sparing operations in Marfan syndrome. J Am Coll Cardiol.
    PMID: 24384138
  10. Gott VL et al. (1999) — Replacement of the aortic root in patients with Marfan's syndrome. N Engl J Med.
    PMID: 10228192
  11. De Paepe A et al. (1996) — Revised diagnostic criteria for the Marfan syndrome. Am J Med Genet.
    PMID: 8723076
  12. Meijboom LJ et al. (2005) — Outcome of pregnancy in women with Marfan syndrome. Obstet Gynecol.
    PMID: 15814833

Back to Table of Contents

Connections

Back to Table of Contents